Estradiol-3-hemisuccinate | 43085-91-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: Estradiol-3-hemisuccinate
• 英文别名: 17β-hydroxyestra-1,3,5(10)-trien-3-yl hemisuccinate；succinic acid mono-[3-hydroxy-estratrien-(1.3.5(10))-yl-(17β)-ester]；Bernsteinsaeure-mono-((8R)-3-hydroxy-13c-methyl-(8rH.9tH.14tH)-7.8.9.11.12.13.14.15.16.17-decahydro-6H-cyclopenta[a]phenanthrenyl-(17c)-ester)；Bernsteinsaeure-mono-[3-hydroxy-oestratrien-(1.3.5(10))-yl-(17β)-ester]；Bernsteinsaeure-mono-(3-hydroxy-oestratrien-(A)-yl-(17β)-ester)；4-[[(8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl]oxy]-4-oxobutanoic acid
• CAS: 43085-91-2
• 化学式: C₂₂H₂₈O₅
• 分子量: 372.461
• InChiKey: HMLANSNZCAYLMK-FNIAAEIWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  83.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  Estradiol-3-hemisuccinate 在 甲酸 、 三乙胺 、 N,N'-二环己基碳二亚胺 作用下， 以 氯仿 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 (13-amino-4,7,10-trioxatridecanyl)-3-(17β-hydroxyestra-1,3,5(10)-trien-3-yl)oxycarbonylpropanamide
  参考文献：
  名称：

  Estrogen conjugation and antibody binding interactions in surface plasmon resonance biosensing

  摘要：

  Thioether-linked 3-mercaptopropionic acid derivatives of 17 beta-estradiol and estrone were formed at the A-ring 4-position of the steroids by substitution of their 4-bromo analogues. The carboxylic acid terminal was used to link to an oligoethylene glycol (OEG) chain of 15-atoms in length. The OEG derivative of 17 beta-estradiol was then in situ immobilized on a carboxymethylated dextran-coated gold sensor surface used to detect refractive index changes upon protein binding to the surface by surface plasmon propagation in a BIAcore surface plasmon resonance (SPR) instrument. TWO other estradiol-OEG derivatives with Mannich reaction linkage at the 2-position and hemisuccinate linkage at the 3-position were also immobilized on the sensor surfaces for comparison. Binding performance between these immobilized different positional conjugates and monoclonal anti-estradiol antibody, raised from a G-position conjugate, clearly demonstrated that both 2- and 4-conjugates, not conjugated through existing functional groups, gave strong antibody bindings, whereas the 3-conjugate through an existing functional group (3-OH) gave very little binding (2% compared to the 2-conjugate). Both 2- and 4-position conjugates were then applied in a highly sensitive estradiol SPR immunoassay with secondary antibody mediated signal enhancement that gave up to a 9.5-fold signal enhancement of primary antibody binding, and a detection limit of 25 pg/mL was achieved for a rapid and convenient flow-through immunoassay of estradiol. (c) 2006 Elsevier Inc. All rights reserved.

  DOI：

  10.1016/j.steroids.2006.03.004
• 作为产物：
  描述：

  succinic acid mono-[3-benzyloxy-estratrien-(1.3.5(10))-yl-(17β)-ester] 在 钯 、 溶剂黄146 作用下， 生成 Estradiol-3-hemisuccinate
  参考文献：
  名称：

  Process for the preparation of derivatives of estradiol

  摘要：

  公开号：

  US02167132A1

文献信息

• Vaginal delivery system
  申请人：Bayer Schering Pharma Oy

  公开号：EP2062568A1

  公开（公告）日：2009-05-27

  The present invention is related to an intravaginal delivery system for the controlled release of a progestogen and an estrogen, comprising additionally a therapeutically active or a health-promoting substance (1) capable of giving and/or enhancing the protection against bacterial and fungal infections, and/or enhancing the protection against sexually transmitted diseases. The delivery system consists of one or more compartments (2,4,5), one of each comprising a core (7) and a membrane (3) encasing the core, said core and membrane essentially consisting of a same or different polymer composition, wherein at cast one of the cores comprises a progestogen or a mixture of a progestogen and an estrogen, and another core may comprise an estrogen or a progestogen, and wherein the membrane or the surface of the membrane or at least one of the cores comprises said therapeutically active or a health-promoting substance.

  本发明涉及一种用于控制释放孕激素和雌激素的阴道内给药系统，该系统还包括一种具有治疗活性或促进健康的物质（1），该物质能够提供和/或增强对细菌和真菌感染的保护，和/或增强对性传播疾病的保护。该给药系统由一个或多个隔室（2、4、5）组成，每个隔室包括一个内核（7）和包裹内核的膜（3），所述内核和膜基本上由相同或不同的聚合物组成，其中至少一个内核包括孕激素或孕激素和雌激素的混合物，另一个内核可包括雌激素或孕激素，膜或膜的表面或至少一个内核包括所述治疗活性物质或促进健康的物质。
• PEARLMAN; DeMEIO, Journal of Biological Chemistry, 1949, vol. 179, # 3, p. 1141 - 1145
  作者：PEARLMAN、DeMEIO

  DOI：——

  日期：——
• Estradiol derivatives and process for preparing same
  申请人：REZSO WEISZ

  公开号：US02295980A1

  公开（公告）日：1942-09-15
• VAGINAL DELIVERY SYSTEM
  申请人：Bayer Schering Pharma Oy

  公开号：EP2227220A1

  公开（公告）日：2010-09-15
• Matrix-Controlled Transdermal Therapeutic System Based on an Adhesive for Administering Norelgestromin or the Combination Thereof with an Estrogen
  申请人：Wilhelm Martina

  公开号：US20080279915A1

  公开（公告）日：2008-11-13

  The invention relates to a transdermal therapeutic system comprising an active-ingredient-impermeable top layer, an active-ingredient-containing matrix and a removable protective layer, the matrix comprising or consisting of norelgestromin and an optional oestrogen as active ingredients as well as also a pressure-sensitive hot-melt adhesive and optional auxiliaries.